Hativ electrocardiogram monitoring on Patients with Chemotherapy

Chonnam National University Hospital Hwasun Hospital0 个研究点目标入组 300 人开始时间: 待定最近更新: 2024年5月27日

试验速览

暂无简介。

•Adults aged 19 or older who own a smartphone.
•Patients currently taking oral anticancer drugs for solid tumors, who have undergone an electrocardiogram within the past year as per the study enrollment criteria.
•(Thyroid cancer/Breast cancer/Lung cancer: Abemaciclib, Alectinib, Capecitabine, Ceritinib, Crizotinib, Ibrutinib, Lapatinib, Lazertinib, Lenvatinib, Lorlatinib, Osimertinib, Ponatinib, Ribociclib, Sorafenib, Sunitinib, Vandetanib, Vemurafenib)

•Individuals with physical disabilities preventing the use of the portable electrocardiogram device, hativ®.
•Individuals with intracardiac devices such as pacemakers, ICD, CRT, VAD.
•Subjects who are unable to read the informed consent form (illiterate, foreigners, etc.).
•Patients deemed inappropriate for participation in the clinical study based on the judgment of the researchers

发起方

Chonnam National University Hospital Hwasun Hospital